Dengwei He

Prof. Dengwei He

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2023 in Phytotherapy Research
Verified
Journal Article
Closed access
KNKai‐Nan Ni
Kai‐Nan Ni
LYLin Ye
Lin Ye
YZYe‐Jin Zhang
Ye‐Jin Zhang
JFJia‐Wei Fang
Jia‐Wei Fang
TYTao Yang
Tao Yang
DHDengwei He
Dengwei He

15 September 2021 in Orthopaedic Surgery
Verified
Journal Article
Open access
PDF file
ZCZhenzhong Chen
Zhenzhong Chen
CLChao Lou
Chao Lou
WYWeiyang Yu
Weiyang Yu
DHDengwei He
Dengwei He
Objective: The aim of this study was to compare the radiological features of intravertebral clefts (IVC) between Kümmell disease (KD) and acute osteoporotic vertebral compression fracture (OVCF).Materials and Methods: This is a retrospective study. A total of 79 patients with IVC from January 2014 to December 2018 were included in this study. There were 22 men and 57 women, with an average of 73.5 years. Based on the exact time interval from injury to treatment and the pathological examination results, the patients were divided into KD group (44 patients) and acute OVCF group (35 patients). The two groups were compared by the margin sclerosis of IVC, vertebra and pedicle ossification, stress fracture of the spinous process, paravertebral callus, the shape of IVC, cleft in the adjacent disc, and flatness of IVC's margin from plain radiographs and computed tomography (CT). The two groups were compared by the IVC content, double‐line sign, and signal of fracture vertebral from their magnetic resonance imaging (MRI).Results: There were no significant differences in sex, age, and fracture distribution between the KD group and the acute OVCF group. IVC was present in both the KD group and the acute OVCF group. Six radiological features were only present in the KD group, including sclerosis of the cleft margin (95.5%, 42/44), ossification of the fractured vertebrae (100%, 44/44), ossification of the pedicle (31.8%, 14/44), double‐line sign (27.3%, 12/44), stress fracture of the spinous process (13.6%, 6/44), and even formation of paravertebral callus (18.2%, 8/44). Although there were statistical differences in the other four radiological features of content of IVC (P = 0.02), cleft sign in adjacent intervertebral disc (P < 0.01), margin of IVC (P = 0.02), and the shape of IVC (P = 0.01) between the KD group and acute OVCF group, these characteristics could be found in both groups.Conclusion: IVC could present in patients with both KD and acute OVCF; however, we found that marginal cleft sclerosis, vertebral and pedicle ossification, double‐line sign, spinous process fracture, and formation of paravertebral callus are unique radiological features of KD and could be used for differentiation of KD from acute OVCF with IVC.

29 November 2022 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
BPBin Pan
Bin Pan
LZLin Zheng
Lin Zheng
SLShijie Liu
Shijie Liu
JFJiawei Fang
Jiawei Fang
CLChao Lou
Chao Lou
DHDengwei He
Dengwei He
Bone metabolic homeostasis is largely dependent on the dynamic balance between osteoblasts and osteoclasts. MicroRNAs (miRNAs) play critical roles in regulating bone metabolism. In this study, we explored the role of a new miRNA (miR-148a) in osteoporosis. We compared the bone phenotype between miR-148a knockout (KO) mice and the wild-type (WT) littermates. We found miR-148a KO mice exhibited an increased bone mass phenotype and decreased osteoclastogenesis compared to the WT group. In vitro, miR-148a overexpression promoted osteoclastogenesis and bone resorption function. Mechanistically, NRP1 was identified as a novel direct target of miR-148a, and NRP1 silencing reversed the effect of miR-148a knockout. In OVX and calvarial osteolysis models, miR-148a KO protects mice against excessive bone resorption, while miR-148a agomiR/AAV-shNRP1 accelerates pathologic bone loss. Finally, the miR-148a level was found to be positively correlated with β-CTX in postmenopausal osteoporosis (PMOP) serum specimens. In summary, our findings revealed that miR-148a genetic deletion ameliorates bone loss under physiological and pathological conditions by targeting NRP1. In osteoclast-related bone metabolic diseases such as PMOP, miR-148a may be an attractive therapeutic target in the future.

26 November 2021 in Frontiers in Pharmacology
Verified
Journal Article
Open access
BPBin Pan
Bin Pan
LZLin Zheng
Lin Zheng
JFJiawei Fang
Jiawei Fang
YLYe Lin
Ye Lin
HLHehuan Lai
Hehuan Lai
DHDengwei He
Dengwei He
Osteoporosis is characterized by a decrease in bone mass and destruction of the bone microarchitecture, and it commonly occurs in postmenopausal women and the elderly. Overactivation of osteoclasts caused by the inflammatory response or oxidative stress leads to osteoporosis. An increasing number of studies have suggested that intracellular reactive oxygen species (ROS) are strongly associated with osteoclastogenesis. As a novel angiotensin (Ang) II receptor blocker (ARB), azilsartan was reported to be associated with the inhibition of intracellular oxidative stress processes. However, the relationship between azilsartan and osteoclastogenesis is still unknown. In this study, we explored the effect of azilsartan on ovariectomy-induced osteoporosis in mice. Azilsartan significantly inhibited the receptor activator of nuclear factor-κB ligand (RANKL)-mediated osteoclastogenesis and downregulated the expression of osteoclast-associated markers (Nfatc1, c-Fos, and Ctsk) in vitro. Furthermore, azilsartan reduced RANKL-induced ROS production by increasing the expression of nuclear factor erythroid 2-related factor 2 (Nrf2). Mechanistically, azilsartan inhibited the activation of MAPK/NF-κB signaling pathways, while Nrf2 silencing reversed the inhibitory effect of azilsartan on MAPK/NF-κB signaling pathways. Consistent with the in vitro data, azilsartan administration ameliorated ovariectomy (OVX)-induced osteoporosis, and decreased ROS levels in vivo. In conclusion, azilsartan inhibited oxidative stress and may be a novel treatment strategy for osteoporosis caused by osteoclast overactivation.

1 October 2021 in Biochemical Pharmacology
Verified
Journal Article
Closed access
KJKangtao Jin
Kangtao Jin
LZLin Zheng
Lin Zheng
LYLin Ye
Lin Ye
ZXZiang Xie
Ziang Xie
JGJiawei Gao
Jiawei Gao
DHDengwei He
Dengwei He

21 January 2024 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
TYTao Yang
Tao Yang
SLShijie Liu
Shijie Liu
HMHaiwei Ma
Haiwei Ma
HLHehuan Lai
Hehuan Lai
CWChengdi Wang
Chengdi Wang
DHDengwei He
Dengwei He